Analysis of efficacy and safety of tacrolimus extended-release formulation on prevention of rejection and GVHD in allo-HSCT patients
Not Applicable
- Conditions
- allo hematopoietic stem cell transplantations of hematopoietic disorders
- Registration Number
- JPRN-UMIN000008004
- Lead Sponsor
- Tokyo Women's Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
1. patients who had allergic reaction to tacrolimus 2. patients with the administration ofcyclosporin A or bosentan 3. patients with the administration of potassium-conserving diuretic 4. patients who are pregnant or have the possiblity of pregnancy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Analysis of efficacy and safety of tacrolimus extended-release formulation on prevention of rejection and GVHD
- Secondary Outcome Measures
Name Time Method